This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2000 Jul 19;92(14):1183-4.

doi: 10.1093/jnci/92.14.1183.

More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

C Magnusson, I Persson, H O Adami

PMID: 10904095
DOI: 10.1093/jnci/92.14.1183

Comment

More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

C Magnusson et al. J Natl Cancer Inst. 2000.

. 2000 Jul 19;92(14):1183-4.

doi: 10.1093/jnci/92.14.1183.

Authors

C Magnusson, I Persson, H O Adami

PMID: 10904095
DOI: 10.1093/jnci/92.14.1183

No abstract available

PubMed Disclaimer

Comment on

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Ross RK, Paganini-Hill A, Wan PC, Pike MC. Ross RK, et al. J Natl Cancer Inst. 2000 Feb 16;92(4):328-32. doi: 10.1093/jnci/92.4.328. J Natl Cancer Inst. 2000. PMID: 10675382

Similar articles

Breast cancer and hormone-replacement therapy: the Million Women Study.
Garton M. Garton M. Lancet. 2003 Oct 18;362(9392):1328; author reply 1330-1. doi: 10.1016/S0140-6736(03)14590-4. Lancet. 2003. PMID: 14575985 No abstract available.
Re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
Archer DF, Bush T, Nachtigall LE. Archer DF, et al. J Natl Cancer Inst. 2000 Dec 6;92(23):1950-2. doi: 10.1093/jnci/92.23.1950. J Natl Cancer Inst. 2000. PMID: 11106695 No abstract available.
Estrogen-progestin replacement therapy: regulatory action needed.
Pike MC, Ross RK. Pike MC, et al. Breast Cancer Res. 2002;4(6):222-3. doi: 10.1186/bcr550. Epub 2002 Oct 8. Breast Cancer Res. 2002. PMID: 12473167 Free PMC article.
Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.
Schairer C. Schairer C. Breast Cancer Res. 2002;4(6):244-8. doi: 10.1186/bcr540. Epub 2002 Oct 7. Breast Cancer Res. 2002. PMID: 12473171 Free PMC article. Review.
Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy.
Santen RJ, Pinkerton J, McCartney C, Petroni GR. Santen RJ, et al. J Clin Endocrinol Metab. 2001 Jan;86(1):16-23. doi: 10.1210/jcem.86.1.7269. J Clin Endocrinol Metab. 2001. PMID: 11231971 Review. No abstract available.

See all similar articles

Cited by

The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms.
Joung KH, Jeong JW, Ku BJ. Joung KH, et al. Biomed Res Int. 2015;2015:920618. doi: 10.1155/2015/920618. Epub 2015 Mar 19. Biomed Res Int. 2015. PMID: 25866823 Free PMC article. Review.
Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.
Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Møller S, Rank F, Ottesen B, Lynge E. Stahlberg C, et al. Br J Cancer. 2004 Aug 16;91(4):644-50. doi: 10.1038/sj.bjc.6601996. Br J Cancer. 2004. PMID: 15238982 Free PMC article.
Hormone replacement therapy and the breast.
Dixon JM. Dixon JM. BMJ. 2001 Dec 15;323(7326):1381-2. doi: 10.1136/bmj.323.7326.1381. BMJ. 2001. PMID: 11744551 Free PMC article. No abstract available.
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. Miricescu D, et al. Int J Mol Sci. 2020 Dec 26;22(1):173. doi: 10.3390/ijms22010173. Int J Mol Sci. 2020. PMID: 33375317 Free PMC article. Review.
Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.
Baber R, Hickey M, Kwik M. Baber R, et al. Drug Saf. 2005;28(12):1085-100. doi: 10.2165/00002018-200528120-00004. Drug Saf. 2005. PMID: 16329712 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information